Artwork

Content provided by touchpodcast. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by touchpodcast or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Emerging second-line treatment approaches in advanced NSCLC: The role of ADCs

35:04
 
Share
 

Manage episode 402284859 series 3389426
Content provided by touchpodcast. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by touchpodcast or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

touchTALKS for touchONCOLOGY

Listen to a leading expert in lung cancer discuss the role of antibody–drug conjugates (ADCs) in the treatment of patients with advanced non-small cell lung cancer, including their structure and mechanistic rationale, the latest clinical trial data and the optimal management of patients receiving ADCs.

The expert

  • Dr Rebecca Heist – Massachusetts General Hospital, Boston, MA, USA

This touchPODCAST is for HCPs only.

This activity is funded by an independent medical education grant from AstraZeneca and is jointly provided by USF Health and touchIME.

For further information visit our website: touchoncology.com

  continue reading

104 episodes

Artwork
iconShare
 
Manage episode 402284859 series 3389426
Content provided by touchpodcast. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by touchpodcast or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

touchTALKS for touchONCOLOGY

Listen to a leading expert in lung cancer discuss the role of antibody–drug conjugates (ADCs) in the treatment of patients with advanced non-small cell lung cancer, including their structure and mechanistic rationale, the latest clinical trial data and the optimal management of patients receiving ADCs.

The expert

  • Dr Rebecca Heist – Massachusetts General Hospital, Boston, MA, USA

This touchPODCAST is for HCPs only.

This activity is funded by an independent medical education grant from AstraZeneca and is jointly provided by USF Health and touchIME.

For further information visit our website: touchoncology.com

  continue reading

104 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide